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We report a 3-year-old girl with steroid resistant nephrotic syndrome (NS) who devel-
oped nephrotoxicity by low-dose cyclosporin (CsA) treatment.  Initial prednisolone
(PSL) treatment and subsequent additional cyclophosphamide treatment were not
successful in leading her into remission.  The first renal biopsy finding revealed neither
a glomerular nor interstitial change.  CsA therapy was initiated in addition to ongoing
glucocorticoid therapy at 6 months from the time of onset. Proteinuria disappeared 3
weeks later and the patient went into complete remission. After experiencing the first
relapse, the patient was gradually weaned from CsA, and treatment continued with 30
to 50 ng/mL of trough concentration.  No elevations of the serum creatinine, serum
urea, serum potassium, excretion of urinary β2-microglobulin, or urinary N-acetyl-β-
D-glucosaminidase were demonstrated in the follow-up.  A second renal biopsy
specimen obtained 1 year later showed a tubulo-interstitial change, containing tubular
atrophy and interstitial fibrosis, both of which are consistent with the morphological
change associated with CsA nephrotoxicity.  A follow-up biopsy should be done in
order to evaluate the CsA nephrotoxicity, regardless of the treatment dosage.
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Cyclosporin (CsA) is a very effective immuno-
suppressive agent that has been used in the
treatment of steroid dependent or resistant
nephrotic syndrome (NS) (Meyrier et al., 1991;
Niaudet et al., 1991; Niaudet, 1992).  However,
CsA may have adverse effects upon the
kidneys, and long-term treatment is associated
with irreversible renal damage consisting of
focal glomerular sclerosis and interstitial
nephritis (Mihatsch et al., 1994).  Nephrotoxicity
has occurred in patients following high doses of
CsA, and the likelihood of its occurrence
depends on the trough concentration level of the
drug  (Col l abora t ive  S tudy  Group  o f
Sandimmun in Nephrotic Syndrome, 1991).  In
this paper we describe a case of a NS patient
suffering from CsA nephrotoxicity though she
was treated with a low blood concentration.
Patient Report
In September 1996, a 3-year-old girl was refer-
red to us from a satellite hospital with symp-
toms of NS consisting of massive proteinuria,
edema and oliguria, which had begun 4 months
earlier.  She had been treated by prednisolone
(PSL) and subsequent additional cyclophosph-
amide treatment but the disease was not re-
solved by means of these agents.   At the time of
admission to our hospital, she retained symp-
toms of NS—anasarca, ascites, oliguria (150 to
250 mL/24 h) and hypertension (from 58 to 112
mmHg).   Laboratory findings revealed hypo-
proteinemia (serum total protein: 4.6 g/dL,
serum albumin: 2.3 g/dL) and hypercholester-
olemia (serum total cholesterol: 479 mg/dL),
though the serum urea level (8 mg/dL) and
serum creatinine level (0.2 mg/dL) were nor-
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mal.  Urinalysis showed massive proteinuria
(over 600 mg/dL concentration in the morning
urine and 4.2 g/24 h in urinary protein excre-
tion), but hematuria and abnormal urinary
sediment were not shown (Table 1).  On Sep-
tember 25, a needle renal biopsy was performed
from the lower pole of the right kidney.  In the
renal biopsy specimen, which contained 8
glomeruli, only 1 glomerulus showed global
sclerosis; the other glomeruli and tubulo-
interstitia did not show any morphological
change (Fig. 1).  Any depositions of immuno-
globulins and components, which were exa-
mined by immunofluorescent study, were not
observed in the glomeruli.  Beginning on
October 21, CsA was administered at a 50 mg/
day (3.5 mg/kg/day) initial dose in addition to
the ongoing PSL treatment.  Blood concentra-
tion of the drug was measured regularly twice a
week by fluorescence polarization immuno-
assay method using monoclonal antibody, and
was maintained in a range of 60 to 90 ng/mL,
and never exceeded 100 ng/mL during the
entire period of treatment (Fig. 2).  Three weeks
after CsA treatment began, proteinuria appear-
ed to be minimizing and had completely dis-
Table 1.  Laboratory data on admission
White blood cell (/µL) 12,000
Red blood cell (/µL)      455 × 104
Hemoglobin (g/dL)        13.3
Hematocrit (%)        39.3
Platelet (/µL)        37.3 × 104
Na (mmol/L)      138
K (mmol/L)          4.0
Cl (mmol/L)      100
Blood urea nitrogen (mg/dL)          8
Cr (mg/dL)          0.2
Urea acid (mg/dL)          4.2
Ca (mg/dL)          8.6
P (mg/dL)          3.7
Serum total protein (g/dL)          4.6
Serum albumin (g/dL)          2.3
Total cholesterol (mg/dL)      479
Urinalysis
pH          7.0
Protein (mg/dL)      600 (4.2 g/day)
Glucose Negative
Occult blood Negative
Sediment
Red blood cell (/hpf)          1–4
White blood cell (/hpf)          5–9
U-β2MG (µg/L)        94
U-NAG (IU/L)          8.0
hpf, high power field; U-β2MG, urinary β2  microglob-
ulin; U-NAG, urinary N-acethyl-β-glucoseaminidas.
Fig. 1.  Light micrograph of first renal biopsy specimens showing normal tubulointerstitia and glomerulus
(periodic acid-Schiff stain × 200).
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appeared 1 month following administration.
On December 19, when the PSL dose was re-
duced to 20 mg/48 h every other day, the patient
relapsed with no apparent cause.  After the PSL
dose was temporarily raised, the relapse was
resolved, and the patient was discharged on
February 24, 1997.  CsA was tapered, and treat-
ment was continued in a range of 30 to 50 ng/
mL of whole blood concentration.  The CsA
dose ranged from 1 mg/kg/day to 1.5 mg/kg/day
during the follow-up period.  PSL was simulta-
neously continued in combination with a small
amount of CsA.  Blood and urinary analyses
were performed regularly.  No elevation of the
serum creatinine, urea, and potassium levels
and excretion of urinary b 2-microglobulin and
N-acetyl- b -D-glucosaminidase were demon-
strated during the follow-up period.  In order to
evaluate the subsequent renal morphological
change, a second renal biopsy was performed 1
year later on October 29, 1997.  Eighteen glo-
meruli were obtained, 17 of which showed mild
or moderate mesangial cell proliferation, though
neither segmental lesion nor global sclerosis was
seen (Fig. 3A).  Morphological changes were
unexpectedly found in the tubulointerstitia,
which is regarded as a feature of CsA nephro-
Fig. 2.  Clinical course of the present patient.   PSL, prednisolone; CPM, cyclophosphamide; CsA, cyclo-
sporin; TP, serum total protein; Cr, serum creatinine; U- b 2 MG, urinary b 2-microglobulin.
toxicity.  Tubular atrophy and interstitial fibr-
osis were seen focally in some fields by light
microscopy (Fig. 3B).  Vacuolization in tubular
epithelial cells was not identified.  No elevation
of the serum creatinine (0.2 mg/dL), serum urea
(14 mg/dL), or excretion of urinary b 2-micro-
globulin (63 m g/L) was demonstrated at the
time of the second biopsy.  In consideration of
the above histological findings, CsA treatment
was discontinued in July, 1998.
Discussion
Our patient suffered from nephrotoxicity within
the 1st year of CsA administration, although she
had been treated with a low-dose treatment.
The CsA dose was reduced within the first 2
months, and continued at 30 to 50 ng/mL of
trough concentration during almost all of the
treatment period.  CsA nephrotoxicity is chara-
cterized as hyalinization of afferent arteries,
tubular atrophy and stripped interstitial fibrosis
(Bergstein, 1992); tubular atrophy and stripped
interstitial fibrosis were seen in the present pa-
tient.  The mesangial proliferation in the present
patient is not considered to be a morphological
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change indicative of CsA nephrotoxicity, but as
a glomerular change seen in cases of diffuse
mesangial hypercellularity, which was addres-
sed by the International Study of Kidney Dis-
ease in Children (1981).
Fig. 3.  Light micrographs of second renal biopsy specimens showing mesangial proliferation (A:
periodicacid-Schiff stain × 400), stripped interstitial fibrosis and tubular atrophy (B: PAM × 400).
It has been considered that the deterioration
of renal function depends on the trough concen-
tration level of the treatment drug, and that
long-term use of CsA results in chronic renal in-
jury, which is not corroborated by biochemical
A
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laboratory findings (Collaborative Study Group
of Sandimmun in Nephrotic Syndrome, 1991;
Tanaka et al., 1993).  In previous literature
authored by Yoshikawa and colleagues (1995),
7 of 13 patients with steroid-dependent NS,
managed with 100 ng/mL of whole blood level
for 2 years, suffered subsequent chronic ne-
phrotoxicity, although none of these patients
demonstrated elevation of both serum creati-
nine and urinary β2-microglobulin during the
administration period.  Other published reports
concerning a moderate dose of CsA treatment
showed a relatively high incidence of morpho-
logical change.  The reported incidence of ne-
phrotoxicity among patients with NS ranges
from 25 to 63% (Brodehl et al., 1988; Niaudet
et al., 1988; Sieberth et al., 1992).  Conversely,
a publication by Gregory and colleagues (1996)
describing long-term use has drawn attention to
a relatively low incidence; the authors showed
that the incidence of nephrotoxicity in biopsy
specimens obtained after 12 to 41 months of
therapy is 17%.
Based on reported studies, the incidence of
nephrotoxicity in patients with steroid resistant
nephrotic syndrome is higher than that in pa-
tients with steroid dependent nephrotic syn-
drome:  22 to 66% versus 0 to 10% (Capodicasa
et al., 1986; Niaudet et al., 1988, 1991; Neuhaus et
al,.  1992).  However , steroid resistant nephrotic
syndrome itself carries a substantial risk of
chronic renal insufficiency and end-stage renal
disease (Mampaso et al., 1981).  Other studies
showed that the risk of CsA nephrotoxicity was
associated with increased patient age, preexist-
ing deteriorating renal function, hypertension
and decreased renal blood perfusion (Thiel et
al., 1986; Feutren et al., 1992).  We found no
evidence, however, to explain why our patient
suffered CsA nephrotoxicity in response to a
relatively small dose.   We speculate that the
condition of the patient’s illness at the time of
commencement of CsA treatment may relate to
a increased risk for nephrotoxicity.  When CsA
was initiated, she still had symptoms of NS in-
cluding massive proteinuria, edema, hyperten-
sion and oliguria, suggesting the existence of
poor renal blood perfusion and decreased renal
function which were not associated with detect-
able laboratory data.  To our knowledge, pre-
existing renal dysfunction is one of the high risk
factors of increased CsA nephrotoxicity.  In
previous studies using ischemic rat kidneys,
poor renal blood perfusion has proven to be one
of the increasing risk factors (Jablonski et al.,
1986; Thiel et al., 1986).  We consider that CsA
administration on the hypoperfusion kidney in
the initial presentation might increase CsA in-
toxication, and result in subsequent tubulointer-
stitial change.  Accordingly, regardless of the
proceeding CsA dose, a careful follow-up, in-
cluding re-evaluation of histological changes by
second renal biopsy, is warranted in this patient.
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